At the American Academy of Dermatology’s annual meeting, researchers presented study findings supporting the safety and efficacy of ATX-101 in reducing the appearance of a double chin.
ATX-101, marketed as Kybella (deoxycholic acid; Allergan), was approved in April 2015 for the treatment of moderate-to-severe submental fat. The product is an injectable organic acid identical to one produced in the body, and works by breaking down fat cell membranes but keeping surrounding tissues intact. The damaged fat cells are then flushed out by the body’s natural processes.
Patients are administered a series of subcutaneous (SC) injections over the course of up to 6 sessions. In clinical trials, these injections have demonstrated safety and tolerability when administered no sooner than 4 weeks apart. The most commonly reported adverse effects were temporary bruising, swelling, and discomfort.
Follow-up data has shown sustained positive effects unlike other injectable treatments that require maintenance doses. Patients have reported increased self-esteem and satisfaction. In addition, reduced chin volume with no unwanted skin sagging has been reported in >90% of patients.
“ATX-101 represents an important, nonsurgical treatment for the increasing demand for submental fat reduction,” explained Dr. Saad Al Sogair, board certified dermatologist and presenter at the meeting . “Moreover, the treatment serves as a regulated alternative to unregulated, compounded and misbranded products with unknown quality, safety and efficacy.”
Kybella is supplied as 10mg/mL strength injections in 2mL single-use vials.
For more information call (818) 587-4500 or visit Kythera.com.